Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CTAD 2022

Popular new uploads

View all
2:10
FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?
Alvaro Pascual-Leone • 9 Jan 2023
2:41
Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease
Carla Abdelnour • 29 Nov 2022
3:06
The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia
Hussein Yassine • 30 Nov 2022
4:37
Long-term transdermal nicotine for the treatment of mild cognitive impairment
Paul Newhouse • 23 Nov 2022

Lecanemab news

View all
5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain • 6 Dec 2022
5:24
Lecanemab: a review
Alvaro Pascual-Leone • 9 Jan 2023

Novel treatments

View all
7:29
New pivotal study using photobiomodulation in Alzheimer’s treatment
Jacques Touchon • 9 Dec 2022
3:53
Nilotinib: a potential repurposed treatment for Alzheimer’s disease?
Charbel Moussa • 28 Nov 2022

Improving diagnosis & prognostication

View all
2:52
Speech biomarker for cognition: a novel marker for AD clinical trial screening
Nicklas Linz • 8 Dec 2022
3:37
The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD
Paul Kinnon • 21 Nov 2022
6:13
Biomarkers for early detection of Alzheimer’s disease: microRNAs
Bruno Steinkraus • 1 Dec 2022
5:34
Associations between predicted brain age and Alzheimer’s Disease biomarkers
Irene Cumplido-Mayoral • 25 Nov 2022
The content of VJDementia is intended for healthcare professionals